Day 2
Final
Time: Central European Time (CET)
| 09.00 – 09.45 | OPENING SPEECHES |
| Conference Moderators: |
Dimitrios ATHANASIOU, EMA Pediatric Committee , EPF, WDO, EAE Board Member Vasilis KARATZIAS, President, Hellenic Friedreich’s Ataxia Association, Director of the Office of Legal Advisers, NATO Rapid Deployable Corps, Greece |
| Speakers: | Norbert COUESPEL, Chair, Future-Proofing Health Systems Committee, European Health Parliament, 7th edition |
| Konstantinos HATZIDAKIS, Minister for Labor and Social Affairs, Greece | |
| Violeta STOYANOVA-BENINSKA, MD, PhD, MPH Chair of the Committee for Orphan Medicinal Products (COMP), European Medicines Agency (EMA) | |
| Alexander NATZ, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) | |
| Flaminia MACCHIA, Executive Director, Rare Diseases International | |
| 09.45 | SESSION 5 | THINKING OUT OF THE BOX: ALTERNATIVE ACCESS AND FUNDING MODELS FOR RARE DISEASES |
| 09.45 – 10.00 | KEYNOTE SPEECH: RARE IMPACT Simone BOSELLI, Public Affairs Director, EURORDIS-Rare Diseases Europe |
| 10.00 – 11.00 | A. TRANSFORMING ACCESS MODELS FOR RDS |
| Moderator: | Alexander ΝΑΤΖ, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) |
| Panel Discussion: | Declan NOONE, President of the European Haemophilia Consortium (EHC) |
| Thomas BOLS, Head of Government Affairs and Public Policy, EMEA & APAC, PTC Therapeutics | |
| Ana HIDALGO-SIMON, Head of Advanced Therapies Human Medicines Division, European Medicines Agency (EMA) | |
| Discussion – Q&A | |
| 11.00 – 12.00 | B. NEW ACCESS MODELS FOR RD MEDICINES |
| Moderator: | Anja SCHIEL, Chair, Scientific Advice Working Party, EMA, Vice Chair EUnetHTA21, Senior Advisor Norwegian Medicines Agency (NoMA) |
| Keynote Speech: | Alexander ΝΑΤΖ, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) |
| Panel Discussion: | Nerea BLANQUÉ-CATALINA, Senior Vice President Market Access and Pricing, Alira Health |
| Jamie O’ HARA, CEO, HCD Economics | |
| Maciej GAJEWSKI, Executive Director, Head of International Government Affairs and Policy, Alexion Pharmaceuticals | |
| Discussion – Q&A | |
| 12.00 – 13.00 | Expo – Networking Break |
| 13.00 – 14.00 | C. NEW FUNDING MODELS FOR ACCESS |
| Moderator: | Simone BOSELLI, Public Affairs Director, EURORDIS-Rare Diseases Europe |
| Keynote Speech: | The European Perspective on a New Funding for Access to Rare Disease Treatments Tomislav SOKOL, MEP, EPP Group in the European Parliament |
| Panel Discussion: | The Oslo Medicines Initiative Stanislav KNIAZKOV, Technical Officer, Medical Product Regulation at World Health Organization (WHO) |
| Eleni ANTONIOU, Senior Policy Officer, Thalassaemia International Federation (TIF) | |
| Fernando ARNAIZ, Global Access & Healthcare Funding & Financing solutions lead, Roche | |
| Discussion – Q&A | |
| 14.00 – 15.30 | D. NEW FUNDING MODELS FOR RD DRUG DEVELOPMENT |
| Moderator: | Duane SCHULTHESS, Managing Director of Vital Transformation |
| Keynote Speech: | Rare Disease Mega funds Andrew W. LO, Charles E. and Susan T. Harris Professor, Professor, Finance, Director, Laboratory for Financial Engineering, MIT Sloan School of Management |
| Panel Discussion: | Richard MASON, CEO Apollo Therapeutics |
| Devin ROSENTHAL, PhD. Vice President NovaQuest Capital Management | |
| Gergely KRAJCSI, Investment Officer, Growth Capital & Innovation Finance Unit, European Investment Bank (EIB) | |
| Maria da Graça CARVALHO, Member of the European Parliament | |
| Discussion – Q&A | |
| 15.30 – 16.00 | Expo – Networking Break |
| 16.00 – 17.30 | SESSION 6 | RARE DISEASES AS A NATIONAL PRIORITY IN GREECE |
| Designing and implementing national policies, strategies, and programs with the aim of contributing to the well-being and fulfilling the rights of all people living with a rare disease in Greece. | |
| Moderators: | Dimitrios ATHANASIOU, EMA Pediatric Committee , EPF, WDO, EAE Board Member Vasilis KARATZIAS, President, Hellenic Friedreich’s Ataxia Association, Director of the Office of Legal Advisers, NATO Rapid Deployable Corps, Greece |
| Panel Discussion: | Mina GAGA, MD, PhD Alternate Minister of Health, Ministry of Health, Greece |
| Giannis SOTIRIOU, CeO IFET | |
| Michael HIMONAS, General Manager of the Hellenic Association of Pharmaceutical Companies (SFEE) | |
| Dimitrios BOUMPAS, Professor of Pathology-Rheumatology, Medical School, National Kapodistrian University of Athens, President of the Central Health Council (KESY), President of the Medical Society of Athens, Director of the 4th Pathological Clinic, General University Hospital of Athens “ATTIKON”, Member of the Institute of Molecular Biology and Biotechnology, Crete and the Institute of Biomedical Research, Academy of Athens, Greece | |
| Nikos KOSTARAS, General Manager, IQVIA Greece | |
| Pavlina KARASIOTOU, Secretary General of Social Insurance, Ministry for Labor and Social Affairs | |
| Athanassios VOZIKIS, Associate Professor, Laboratory of Health Economics and Management, Economics Department, University of Piraeus | |
| Discussion – Q&A | |
| 17.30 | END OF DAY 2 |
Contact us
Registrations
Greece: Chrysoula Kordouli, Τ: +30 210 6617777 (ext. 204), +30 6946236795, E: [email protected]
Cyprus: Ioanna Antoniou, Τ: +357 99 494 653, E: [email protected]
Sponsorships
Greece: Chrysoula Kordouli, Τ: +30 210 6617777 (ext. 204), +30 6946236795, E: [email protected]
Cyprus: Giorgos Loizou, Τ: +357 99 103323, E: [email protected]
Info & Content
Natalia Toubanaki, T: +30 210 6617 777 (ext. 289), +306947936708, E: [email protected]
BOUSSIAS
338. Kleisthenous Str. 15344, Gerakas, Attiki, Greece
+30 210 6617777
+30 210 6617778
www.boussias.com
+30 210 6617777
+30 210 6617778
www.boussias.com